
Intellectual Property - August 5, 2022
Valo Therapeutics acquires PeptiCHIP technology
Valo Therapeutics has announced the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. This is a strategically important addition for the company as it will […]

Biotech Business - January 10, 2022
Valo Therapeutics acquires IP rights from the University of Helsinki
Valo Therapeutics has announced the acquisition of intellectual property rights from the University of Helsinki for the technology which utilizes pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx’s lead platform, PeptiCRAd. This approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including pathogen specific peptides […]